Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
Neurological complications and infection mechanism of SARS-COV-2
D Wan, T Du, W Hong, L Chen, H Que, S Lu… - Signal Transduction and …, 2021 - nature.com
Abstract Currently, SARS-CoV-2 has caused a global pandemic and threatened many lives.
Although SARS-CoV-2 mainly causes respiratory diseases, growing data indicate that SARS …
Although SARS-CoV-2 mainly causes respiratory diseases, growing data indicate that SARS …
The cGAS–STING pathway drives type I IFN immunopathology in COVID-19
JD Domizio, MF Gulen, F Saidoune, VV Thacker… - Nature, 2022 - nature.com
COVID-19, which is caused by infection with SARS-CoV-2, is characterized by lung
pathology and extrapulmonary complications,. Type I interferons (IFNs) have an essential …
pathology and extrapulmonary complications,. Type I interferons (IFNs) have an essential …
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Although microbial populations in the gut microbiome are associated with COVID-19
severity, a causal impact on patient health has not been established. Here we provide …
severity, a causal impact on patient health has not been established. Here we provide …
SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration
L Zhang, L Zhou, L Bao, J Liu, H Zhu, Q Lv… - Signal transduction and …, 2021 - nature.com
SARS-CoV-2 has been reported to show a capacity for invading the brains of humans and
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
N Suryadevara, S Shrihari, P Gilchuk, LA VanBlargan… - Cell, 2021 - cell.com
Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …
[HTML][HTML] Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
FS Oladunni, JG Park, PA Pino, O Gonzalez… - Nature …, 2020 - nature.com
Vaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease
would benefit from validated small animal models. Here, we show that transgenic mice …
would benefit from validated small animal models. Here, we show that transgenic mice …
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of
immune protection is not fully understood. Here, we applied live bioluminescence imaging …
immune protection is not fully understood. Here, we applied live bioluminescence imaging …
Animal and translational models of SARS-CoV-2 infection and COVID-19
COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical
community is in a race to define and develop effective preventions and treatments. The …
community is in a race to define and develop effective preventions and treatments. The …